Alimera Sciences, Inc. (ALIM) Tops Q4 EPS by 3c
Get Alerts ALIM Hot Sheet
Join SI Premium – FREE
Alimera Sciences, Inc. (NASDAQ: ALIM) reported Q4 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22).
Sees iluvien EU marketing approval by end of Q1, sees meeting with FDA on iluvien during Q2.
For earnings history and earnings-related data on Alimera Sciences, Inc. (ALIM) click here.
Sees iluvien EU marketing approval by end of Q1, sees meeting with FDA on iluvien during Q2.
For earnings history and earnings-related data on Alimera Sciences, Inc. (ALIM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FreightCar America (RAIL) Misses Q4 EPS by 6c, provides guidance
- UBS Upgrades Cognex (CGNX) to Buy
- Adverum Biotechnologies (ADVM) Tops Q4 EPS by 11c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!